Home » Newsletters » BioWorld Science

BioWorld Science

July 5, 2016

View Archived Issues

Takeda and Altos Therapeutics partner to develop ATC-1906 for gastroparesis

Novartis phase I trial triggers milestone payment to MorphoSys

FPA-144 named FDA orphan for gastric/gastroesophageal junction cancer

GSK initiates phase I trial of ICOS agonist antibody GSK-3359609

Janssen Pharmaceutica patents PI3Kbeta inhibitors

Pulmocide discloses respiratory syncytial virus fusion inhibitors

Cancer Research Technology announces PARG inhibitors

Pimco 2664 presents compounds for rheumatoid arthritis

Pfizer reports AXL kinase inhibitors

GlaxoSmithKline presents KMO inhibitors

GenKyoTex divulges NADPH oxidase 1 inhibitors

EMA grants an expansion to orphan drug designation for ATIR-101

Inhibition of ATR and WDR5 shows promising activity in pancreatic ductal adenocarcinoma

New conditionally replicating adenovirus to kill tumorigenic cells

Discovery of novel potent and selective TTK inhibitor CFI-402257

AbbVie receives approval for Duodopa combination intraduodenal gel in Japan

Maruho's Hemangiol receives Japanese approval for treatment of infantile hemangioma

Simponi receives approval in Europe for treatment of polyarticular juvenile idiopathic arthritis

Praluent approved in Japan

Cinfa reports promising topline data for pegfilgrastim biosimilar

TiGenix signs agreement with Takeda for Cx-601, withdraws ChondroCelect marketing authorization

European Commission approves Ongentys in Parkinson's disease

NicOx announces agreement with GHO Capital to transfer commercial operations to new company

EMA's review of conditional MAA for masitinib to follow standard timeline

FDA clears IND for Biohaven's BHV-4157

OncoBEAM RAS CRC test available in Italy

Gemcitabine/S-1/nafamostat mesilate combination shows promise for pancreatic cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...